Euclidean Capital LLC Beam Therapeutics Inc. Transaction History
Euclidean Capital LLC
- $779 Million
- Q1 2024
Shares
2 transactions
Others Institutions Holding BEAM
# of Institutions
241Shares Held
65.6MCall Options Held
311KPut Options Held
777K-
Cathie Wood Ark Investment Management LLC | St. Petersburg, Fl8.18MShares$192 Million1.93% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.58MShares$178 Million0.01% of portfolio
-
Black Rock Inc. New York, NY6.71MShares$157 Million0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA4.51MShares$106 Million0.7% of portfolio
-
Morgan Stanley New York, NY4.12MShares$96.6 Million0.01% of portfolio
About Beam Therapeutics Inc.
- Ticker BEAM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 70,354,600
- Market Cap $1.65B
- Description
- Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen ...